<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="334996">
  <stage>Registered</stage>
  <submitdate>6/04/2010</submitdate>
  <approvaldate>22/11/2010</approvaldate>
  <actrnumber>ACTRN12610001017011</actrnumber>
  <trial_identification>
    <studytitle>Investigation Into The Efficacy And Safety Of Sildenafil  Versus  Natural Progesterone For prevention Of Preterm Labour

A randomized controlled study</studytitle>
    <scientifictitle>Investigation Into The Efficacy And Safety Of Sildenafil Versus  Natural Progesterone For prevention Of Preterm Labour

A randomized controlled study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>prevention Of Preterm Labour</healthcondition>
    <healthcondition>preterm labour</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Antenatal care</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>sildenafil 100 mg vaginally every 12 hours , for 10 weeks prior to scheduled labour</interventions>
    <comparator>progesterone 100 mg tablet vaginally every 12 hours , for 10 weeks prior to scheduled labour</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>preterm birth less than 37 weeks gestation ( assessed clinically ).</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>neonatal outcome ( neonatal death , RDS, intraventricular hemorrhage), assessed clinically &amp; by cranial ultrasound.</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>drug side effects( headache, flushing, dyspepsia, nasal congestion and impaired vision, including photophobia and blurred vision. hypotension, myocardial infarction (heart attack), ventricular arrhythmias, stroke).

assessed clinically</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-pregnant woman 18-24  weeks gestation , the gestational age was estimated by the date of the last  menstrual  period and confirmed by fetal growth measurement with ultrasound.
-Asymptomatic pregnant woman with a history of at least 1 previous  preterm labour( between 20 and 36 weeks plus 6 days gestational age).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-multiple pregnancy
-premature rupture of membrane
-vaginal bleeding
-diabetes
-history of cardiovascular disease
-herniation of the membrane beyond the external cervical os
-congenital anomalies of the fetus
-any fetal or maternal contraindication to tocolysis(fetal asphyxia, intrauterine growth restriction, pre-ecalmpsia , clinical diagnosis of abruption placentae, placenta previa)
-active liver disease, renal impairment.
- recent stroke or heart attack.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>closed  sealed envelope techniqe</concealment>
    <sequence>random numebr table</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/06/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Cairo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>waleed elkhayat</primarysponsorname>
    <primarysponsoraddress>5 Qura Ibn Shourik , Giza , Egypt , 12211</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>waleed elkhayat</fundingname>
      <fundingaddress>5 Qura Ibn Shourik , Giza , Egypt , 12211</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>to use sildenafil to prevent preterm labour with high effeicacy &amp; most safe , as it is an excellent muscle relaxant.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Cairo University hospital research ethics committee (REC)</ethicname>
      <ethicaddress>cairo University , faculty of medicine , Egypt 
kasr Elini street , 11451</ethicaddress>
      <ethicapprovaldate>27/03/2010</ethicapprovaldate>
      <hrec>17/2010</hrec>
      <ethicsubmitdate>1/03/2010</ethicsubmitdate>
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>waleed mamdouh elkhayat</name>
      <address>5 qura ibn shourik street , giza , 12211</address>
      <phone>+20 0105135542</phone>
      <fax />
      <email>waleed_elkhyat@yahoo.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>waleed mamdouh elkhayat</name>
      <address>5 Qura Ibn shourik street off Mourad street ,Giza , Egypt 
post code : 12211.
country : Egypt.</address>
      <phone>+20 0105135542</phone>
      <fax />
      <email>waleed_elkhyat@yahoo.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>waleed mamdouh elkhayat</name>
      <address />
      <phone />
      <fax>+20 0105135542</fax>
      <email>waleed_elkhyat@yahoo.com</email>
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>